指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

区域麻醉与疼痛医学学会、美国疼痛医学学会及美国麻醉医师学会关于静脉氯胺酮输注用于急性疼痛管理的共识指南

Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
指南 / 共识 · Reg Anesth Pain Med · 2018-01-01
一句话结论共识指南支持氯胺酮用于多种急性疼痛场景,包括单独使用、作为阿片类药物辅助及较少程度上的鼻内制剂;急性疼痛的禁忌证与慢性疼痛相似。

该共识指南由美国区域麻醉与疼痛医学学会、美国疼痛医学学会及美国麻醉医师学会相关委员会共同制定,针对急性疼痛中静脉氯胺酮输注的适应证、禁忌证、作为阿片辅助治疗的证据、患者自控氯胺酮镇痛、非肠道剂型及亚麻醉剂量范围等达成共识。证据支持氯胺酮用于多种急性疼痛场景,包括作为单独治疗、阿片类药物辅助治疗,以及较少程度上的鼻内制剂。急性疼痛的禁忌证与慢性疼痛相似,部分基于剂量范围相似的观察。需要更大规模研究评估不同急性疼痛状况,以改善患者选择、确定非肠道氯胺酮替代方案的有效性、界定最佳治疗参数并制定优化安全性和可及性的方案。

要点

  • 证据支持氯胺酮用于多种急性疼痛场景,包括作为单独治疗、作为阿片类药物辅助治疗,以及较少程度上的鼻内制剂。
  • 急性疼痛的禁忌证与慢性疼痛相似,部分基于剂量范围相似的观察。
  • 共识涵盖适应证、急性疼痛与慢性疼痛禁忌证是否不同、氯胺酮作为阿片辅助治疗的证据、患者自控氯胺酮镇痛的证据、非肠道剂型的使用及亚麻醉剂量范围。
  • 委员会就所有问题的答案达成共识。
  • 需要更大规模研究评估不同急性疼痛状况,以改善患者选择、确定非肠道氯胺酮替代方案的有效性、界定最佳治疗参数并制定优化安全性和可及性的方案。

适用人群与场景

  • 急性疼痛患者,包括急诊科、围手术期难治性疼痛个体及阿片耐受患者。

研究设计与关键结果

  • 制定机构为美国区域麻醉与疼痛医学学会、美国疼痛医学学会及美国麻醉医师学会相关委员会;方法为委员会主席根据会议电话中委员会意见提出问题,由3至5名小组成员和委员会主席负责回答个别问题,初步共识达成后全体委员会通过电子邮件和电话会议进一步修订。
  • 共识领域包括适应证、急性疼痛禁忌证及与慢性疼痛禁忌证是否不同、氯胺酮作为阿片辅助治疗的证据、患者自控氯胺酮镇痛的证据、非肠道剂型氯胺酮的使用及亚麻醉剂量范围。
  • 委员会就所有问题的答案达成共识。

证据类型、等级与局限

  • 证据类型:共识指南;推荐强度:原文未给出分级标签。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 证据支持氯胺酮用于多种急性疼痛场景,包括作为单独治疗、作为阿片类药物辅助治疗,以及较少程度上的鼻内制剂。
  • 急性疼痛的禁忌证与慢性疼痛相似,部分基于剂量范围相似的观察。
  • 需要更大规模研究评估不同急性疼痛状况,以改善患者选择、确定非肠道氯胺酮替代方案的有效性、界定最佳治疗参数并制定优化安全性和可及性的方案。

指南或共识出处

  • Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists(Reg Anesth Pain Med)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ketamine infusions have been used for decades to treat acute pain, but a recent surge in usage has made the infusions a mainstay of treatment in emergency departments, in the perioperative period in individuals with refractory pain, and in opioid-tolerant patients. The widespread variability in patient selection, treatment parameters, and monitoring indicates a need for the creation of consensus guidelines.

METHODS: The development of acute pain ketamine guidelines grew as a corollary from the genesis of chronic pain ketamine guidelines. The charge for the development of acute pain ketamine guidelines was provided by the Boards of Directors of both the American Society of Regional Anesthesia and Pain Medicine and the American Academy of Pain Medicine, who approved the document along with the American Society of Anesthesiologists' Committees on Pain Medicine and Standards and Practice Parameters. The committee chair developed questions based on input from the committee during conference calls, which the committee then refined. Groups of 3 to 5 panel members and the committee chair were responsible for answering individual questions. After preliminary consensus was achieved, the entire committee made further revisions via e-mail and conference calls.

RESULTS: Consensus guidelines were prepared in the following areas: indications, contraindications for acute pain and whether they differ from those for chronic pain, the evidence for the use of ketamine as an adjunct to opioid-based therapy, the evidence supporting patient-controlled ketamine analgesia, the use of nonparenteral forms of ketamine, and the subanesthetic dosage range and whether the evidence supports those dosages for acute pain. The group was able to reach consensus on the answers to all questions.

CONCLUSIONS: Evidence supports the use of ketamine for acute pain in a variety of contexts, including as a stand-alone treatment, as an adjunct to opioids, and, to a lesser extent, as an intranasal formulation. Contraindications for acute pain are similar to those for chronic pain, partly based on the observation that the dosage ranges are similar. Larger studies evaluating different acute pain conditions are needed to enhance patient selection, determine the effectiveness of nonparenteral ketamine alternatives, define optimal treatment parameters, and develop protocols optimizing safety and access to care.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

参考来源

  1. Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018. PMID: 29870457. doi:10.1097/AAP.0000000000000806

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。